|
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
Mar 2025 |
Neoplasia |
Myelodysplastic Syndromes (MDS) |
|
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates |
Feb 2025 |
Blood Advances |
Aplastic Anemia |
|
Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
Feb 2025 |
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Genome sequencing in the management of myelodysplastic syndromes and related disorders |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Diagnosis of myelodysplastic syndromes: the classic and the novel |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study |
Feb 2025 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Treatment of high-risk myelodysplastic syndromes |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Treatment of lower-risk myelodysplastic syndromes |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators |
Dec 2024 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria |
Dec 2024 |
Expert Review of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
